8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 3, 2026·SEC
Material company update
Jan 7, 2026·SEC
Enliven Therapeutics, Inc.(ELVN)Earnings, Financials & Key Ratios
ELVN•NASDAQ
Price updated Jun 19, 2026
AboutEnliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.Show more
- Revenue$0
- EBITDA-$119M-14.5%
- Net Income-$104M-16.5%
- EPS (Diluted)-1.83+3.2%
- ROE-26.95%+15.9%
ELVN Key Insights
Enliven Therapeutics, Inc. (ELVN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 93 (top 7%)
✗Weaknesses
- ✗Profits declining 40.5% over 5 years
- ✗Shares diluted 20.4% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ELVN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ELVN Price & Volume
Enliven Therapeutics, Inc. (ELVN) stock price & volume — 10-year historical chart
Loading chart...
ELVN Growth Metrics
Enliven Therapeutics, Inc. (ELVN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-4.16%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM14.58%
Return on Capital
10 Years-64.28%
5 Years-37.92%
3 Years-40.33%
Last Year-31.1%
ELVN Recent Earnings
Enliven Therapeutics, Inc. (ELVN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.38+13.6%
$0.44
Rev
—
—
Q2 2026
Mar 3, 2026Metric
Actual
Est
EPS
$0.48-14.3%
$0.42
Rev
—
$12,500
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.32+25.6%
$0.43
Rev
—
$8,330
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$0.49+7.5%
$0.53
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.38vs $0.44+13.6% | — |
| Q2 2026 | Mar 3, 2026 | $0.48vs $0.42-14.3% | —vs $12,500 |
| Q4 2025 | Nov 12, 2025 | $0.32vs $0.43+25.6% | —vs $8,330 |
| Q3 2025 | Aug 13, 2025 | $0.49vs $0.53+7.5% | — |
Based on last 12 quarters of dataView full earnings history →
ELVN Peer Comparison
Enliven Therapeutics, Inc. (ELVN) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 RVMD | 34.65B | 162.99 | -27.39 | -83.22% | 0.10 | |||
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 AUPH | 2.12B | 16.46 | 7.95 | 20.38% | 99.97% | 64.48% | 0.13 | |
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 ARQT | 3.28B | 26.21 | -201.62 | 91.34% | -0.57% | -1.41% | 0.03 | |
 MGNX | 262.52M | 4.13 | -3.50 | 0.78% | -44.79% | -147.8% | 1.92 | |
 PTCT | 6.55B | 78.98 | 10.15 | 114.51% | -22.58% |
Compare ELVN vs Peers
Enliven Therapeutics, Inc. (ELVN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ELVN Income Statement
Enliven Therapeutics, Inc. (ELVN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 33K | 0 | 0 | 0 | 0 | 0 | 263K | 60K |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | -33K▲ 0% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -263K▲ 0% | -60K▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | - | - |
Gross Profit Growth % | - | - | - | 100% | - | - | - | - | - | - |
Operating Expenses | 8.9M | 10.68M | 24.08M | 9.32M | 24.76M | 38.79M | 83.53M | 104.55M | 119.39M | 115.74M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Selling, General & Admin | 987K | 2.44M | 5.07M | 1.08M | 4.29M | 7.77M | 18.95M | 23.78M | 33.8M | 34.14M |
SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
Research & Development | 7.92M | 8.24M | 19.01M | 8.24M | 20.47M | 31.02M | 64.57M | 80.78M | 85.86M | 81.65M |
R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -8.9M▲ 0% | -10.68M▼ 19.9% | -24.12M▼ 125.9% | -9.32M▲ 61.4% | -24.76M▼ 165.7% | -38.79M▼ 56.7% | -83.53M▼ 115.3% | -104.55M▼ 25.2% | -119.66M▼ 14.4% | -115.79M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - | - | - |
Operating Income Growth % | - | -19.9% | -125.87% | 61.36% | -165.74% | -56.66% | -115.33% | -25.17% | -14.45% | - |
EBITDA | 221K | -11.34M | -24.08M | -9.27M | -24.65M | -38.58M | -83.23M | -104.24M | -119.39M | -115.58M |
EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
EBITDA Growth % | - | -5229.86% | -112.43% | 61.5% | -165.79% | -56.51% | -115.76% | -25.24% | -14.54% | -5.13% |
D&A (Non-Cash Add-back) | 0 | -660K | 33K | 45K | 115K | 215K | 297K | 317K | 263K | 203K |
EBIT | 221K | -11.34M | -23.46M | -9.32M | -24.76M | -38.79M | -83.53M | -104.55M | -119.66M | -110.84M |
Net Interest Income | 0 | 0 | 578K | 483K | 22K | 1.13M | 11.97M | 14.89M | 16.01M | 17.01M |
Interest Income | 0 | 0 | 578K | 483K | 22K | 1.13M | 11.97M | 14.89M | 16.01M | 17.01M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 9.13M | -660K | 653K | -9.65M | 22K | 1.13M | 11.95M | 15.76M | 15.96M | 17.01M |
Pretax Income | 221K▲ 0% | -11.34M▼ 5229.9% | -23.46M▼ 107.0% | -18.97M▲ 19.2% | -24.74M▼ 30.4% | -37.66M▼ 52.2% | -71.58M▼ 90.1% | -88.79M▼ 24.0% | -103.69M▼ 16.8% | -98.78M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
Income Tax | 221K | 0 | 0 | 0 | 0 | 0 | 0 | 232K | 0 | 0 |
Effective Tax Rate % | 100% | 0% | 0% | 0% | 0% | 0% | 0% | -0.26% | 0% | 0% |
Net Income | 0▲ 0% | -11.34M▲ 0% | -23.46M▼ 107.0% | -18.97M▲ 19.2% | -24.74M▼ 30.4% | -37.66M▼ 52.2% | -71.58M▼ 90.1% | -89.02M▼ 24.4% | -103.69M▼ 16.5% | -98.78M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - | - | - |
Net Income Growth % | - | - | -106.96% | 19.17% | -30.44% | -52.23% | -90.07% | -24.36% | -16.48% | -4.16% |
Net Income (Continuing) | 221K | -11.34M | -23.46M | -18.97M | -24.74M | -37.66M | -71.58M | -89.02M | -103.69M | -98.78M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 0.00▲ 0% | -2.62▲ 0% | -5.43▼ 107.3% | -4.31▲ 20.6% | -3.17▲ 26.5% | -6.03▼ 90.2% | -2.01▲ 66.7% | -1.89▲ 6.0% | -1.83▲ 3.2% | -1.57▲ 0% |
EPS Growth % | - | - | -107.25% | 20.63% | 26.45% | -90.22% | 66.67% | 5.97% | 3.17% | 14.58% |
EPS (Basic) | 0.00 | -2.62 | -5.43 | -4.31 | -3.17 | -6.03 | -2.01 | -1.89 | -1.83 | - |
Diluted Shares Outstanding | 4.32M | 4.32M | 4.32M | 4.39M | 7.82M | 6.25M | 35.55M | 47.07M | 56.66M | 62.8M |
Basic Shares Outstanding | 4.32M | 4.32M | 4.32M | 4.39M | 7.81M | 6.25M | 35.55M | 47.07M | 56.66M | 62.8M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ELVN Balance Sheet
Enliven Therapeutics, Inc. (ELVN) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 10.22M | 7.71M | 30.62M | 90.41M | 110.67M | 77.75M | 266.15M | 318.13M | 474.88M | 463.14M |
Cash & Short-Term Investments | 9.67M | 7.38M | 28.91M | 88.22M | 110.02M | 75.54M | 253.15M | 313.44M | 462.62M | 452.4M |
Cash Only | 9.67M | 7.38M | 4.94M | 47.7M | 110.02M | 75.54M | 100.14M | 124.12M | 98.9M | 132.18M |
Short-Term Investments | 0 | 0 | 23.97M | 40.52M | 0 | 0 | 153.01M | 189.32M | 363.73M | 320.22M |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 552K | 323K | 1.72M | 2.18M | 0 | 2.22M | 10.05M | 4.69M | 12.26M | 10.74M |
Total Non-Current Assets | 0 | 0 | 2.67M | 437K | 2.66M | 5.54M | 5.72M | 7.63M | 1.29M | 1.72M |
Property, Plant & Equipment | 0 | 0 | 442K | 349K | 954K | 1.52M | 1.06M | 458K | 417K | 310K |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 88K | 0 | 0 | 54K | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 2.14M | 88K | 1.71M | 3.98M | 4.65M | 7.17M | 873K | 1.41M |
Total Assets | 10.22M▲ 0% | 7.71M▼ 24.6% | 33.3M▲ 332.2% | 90.84M▲ 172.8% | 113.33M▲ 24.8% | 83.3M▼ 26.5% | 271.87M▲ 226.4% | 325.76M▲ 19.8% | 476.17M▲ 46.2% | 464.85M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | - | -24.63% | 332.16% | 172.82% | 24.75% | -26.5% | 226.38% | 19.82% | 46.17% | 214.6% |
Total Current Liabilities | 826K | 1.83M | 4.2M | 6.25M | 5.75M | 9.71M | 25.89M | 15.91M | 16.57M | 11.49M |
Accounts Payable | 431K | 908K | 1.66M | 1.97M | 2.52M | 3.44M | 532K | 1.34M | 2.16M | 1.64M |
Days Payables Outstanding | - | - | 18.34K | - | - | - | - | - | 3K | 11.53K |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 399K | 302K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 5.51M | 0 | 0 | 0 | 0 |
Other Current Liabilities | 196K | 787K | 1.74M | 3.19M | 233K | 320K | 10.36M | 204K | 14.01M | 9.54M |
Current Ratio | 12.38x | 4.21x | 7.29x | 14.47x | 19.24x | 8.00x | 10.28x | 19.99x | 28.66x | 40.32x |
Quick Ratio | 12.38x | 4.21x | 7.29x | 14.47x | 19.24x | 8.00x | 10.28x | 19.99x | 28.66x | 40.32x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 660K | 32.19M | 184K | 160K | 714K | 150.41M | 67K | 0 | 108K | 0 |
Long-Term Debt | 660K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 204K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 108K | 108K |
Other Non-Current Liabilities | 0 | 32.19M | 184K | 160K | 714K | 150.41M | 67K | 0 | 0 | 0 |
Total Liabilities | 1.49M | 1.83M | 4.38M | 6.41M | 6.47M | 160.12M | 25.96M | 15.91M | 16.68M | 11.49M |
Total Debt | 660K | 0 | 0 | 0 | 159K | 323K | 335K | 0 | 399K | 302K |
Net Debt | -9.01M | -7.38M | -4.94M | -47.7M | -109.86M | -75.21M | -99.81M | -124.12M | -98.5M | -131.88M |
Debt / Equity | - | - | - | - | 0.00x | - | 0.00x | - | 0.00x | 0.00x |
Debt / EBITDA | 2.99x | - | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | -40.77x | - | - | - | - | - | - | - | - | 1.14x |
Interest Coverage | - | - | - | - | - | - | - | - | - | - |
Total Equity | -15.53M▲ 0% | -26.32M▼ 69.4% | 28.92M▲ 209.9% | 84.44M▲ 192.0% | 106.86M▲ 26.6% | -76.83M▼ 171.9% | 245.91M▲ 420.1% | 309.85M▲ 26.0% | 459.6M▲ 48.3% | 453.37M▲ 0% |
Equity Growth % | - | -69.41% | 209.88% | 192% | 26.56% | -171.89% | 420.09% | 26% | 48.33% | 230.87% |
Book Value per Share | -3.60 | -6.09 | 6.69 | 19.23 | 13.67 | -12.29 | 6.92 | 6.58 | 8.11 | 7.22 |
Total Shareholders' Equity | -15.53M | -26.32M | -48.85M | 84.44M | 106.86M | -76.83M | 245.91M | 309.85M | 459.6M | 453.37M |
Common Stock | 4K | 4K | 4K | 18K | 1K | 1K | 41K | 49K | 59K | 61K |
Retained Earnings | -19.95M | -31.29M | -54.75M | -96.11M | -45.2M | -82.86M | -154.45M | -243.47M | -347.17M | -370.79M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 32K | 4K | 0 | -149.75K | 141K | 55K | 334K | -382K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ELVN Cash Flow Statement
Enliven Therapeutics, Inc. (ELVN) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -8.79M | -8.78M | -21.88M | -8.53M | -19.13M | -32.08M | -61.27M | -73.19M | -70.3M | -65.47M |
Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
Operating CF Growth % | - | 0.09% | -149.25% | 61.01% | -124.34% | -67.64% | -91.01% | -19.46% | 3.95% | 35.6% |
Net Income | 0 | -11.34M | -23.46M | -18.97M | -24.74M | -37.66M | -71.58M | -89.02M | -103.69M | -98.78M |
Depreciation & Amortization | 0 | 0 | 33K | 45K | 115K | 215K | 297K | 317K | 263K | 597K |
Stock-Based Compensation | 0 | 555K | 899K | 130K | 1.92M | 3.19M | 12.91M | 20.17M | 34.02M | 34.62M |
Deferred Taxes | 0 | 0 | -215K | 0 | -3.81M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -7.93M | 848K | 196K | 9.68M | 3.81M | 1.74M | -4.3M | -118K | 232K | 157K |
Working Capital Changes | -188K | 1.24M | 673K | 583K | 3.57M | 438K | 1.4M | -4.54M | -1.12M | -2.06M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -666K | 477K | 750K | 291K | 1.73M | 411K | -2.25M | 810K | 817K | 78K |
Cash from Investing | 0 | 0 | -24.06M | -461K | -191K | -612K | -148.41M | -36M | -173.84M | -132.74M |
Capital Expenditures | 0 | 0 | -140K | -461K | -191K | -612K | -149K | -44K | -158K | -138K |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 35M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 16.7M | 1.62M | -41.88M | 0 | 873K | 213K | 213K |
Cash from Financing | 11M | 6.49M | 43.58M | 130.51M | -1.02M | -1.8M | 234.29M | 133.16M | 218.87M | 228.69M |
Debt Issued (Net) | 0 | 0 | -2M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 0 | 45.58M | 96.88M | -1.02M | -1.23M | 161.2M | 39.19M | 218.87M | 228.69M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 11M | 6.49M | 0 | 33.63M | 0 | -566K | 73.08M | 93.98M | 0 | 0 |
Net Change in Cash | 2.21M▲ 0% | -2.29M▼ 203.3% | -2.45M▼ 6.9% | 121.52M▲ 5068.2% | -20.34M▼ 116.7% | -34.49M▼ 69.5% | 24.61M▲ 171.3% | 23.98M▼ 2.6% | -25.27M▼ 205.4% | 30.48M▲ 0% |
Free Cash Flow | -8.79M▲ 0% | -8.78M▲ 0.1% | -22.02M▼ 150.8% | -8.99M▲ 59.2% | -19.32M▼ 115.0% | -32.69M▼ 69.2% | -61.42M▼ 87.9% | -73.24M▼ 19.2% | -70.46M▲ 3.8% | -65.6M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - | - | - |
FCF Growth % | - | 0.09% | -150.85% | 59.17% | -114.96% | -69.15% | -87.89% | -19.24% | 3.79% | 11.35% |
FCF per Share | -2.03 | -2.03 | -5.10 | -2.05 | -2.47 | -5.23 | -1.73 | -1.56 | -1.24 | -1.04 |
FCF Conversion (FCF/Net Income) | - | 0.77x | 0.93x | 0.45x | 0.77x | 0.85x | 0.86x | 0.82x | 0.68x | 0.66x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 232K | 0 | 0 |
ELVN Key Ratios
Enliven Therapeutics, Inc. (ELVN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -1804.85% | -33.46% | -25.87% | -250.77% | -84.67% | -32.04% | -26.95% | -21.04% |
Return on Invested Capital (ROIC) | - | - | -23.02% | -110.11% | - | - | -47.26% | -32.82% | -24.34% |
Debt / Equity | - | - | - | 0.00x | - | 0.00x | - | 0.00x | 0.00x |
FCF Conversion | 0.77x | 0.93x | 0.45x | 0.77x | 0.85x | 0.86x | 0.82x | 0.68x | 0.66x |
Related:ELVN Dividend History·ELVN Revenue History·ELVN Price History·ELVN P/E History·ELVN Financial Ratios·ELVN Institutional Holders
ELVN SEC Filings & Documents
Enliven Therapeutics, Inc. (ELVN) SEC filings — annual & quarterly reports (10-K, 10-Q)
ELVN Frequently Asked Questions
Enliven Therapeutics, Inc. (ELVN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Enliven Therapeutics, Inc. (ELVN) grew revenue by 0.0% over the past year. Growth has been modest.
Enliven Therapeutics, Inc. (ELVN) reported a net loss of $98.8M for fiscal year 2025.
Dividend & Returns
Enliven Therapeutics, Inc. (ELVN) has a return on equity (ROE) of -27.0%. Negative ROE indicates the company is unprofitable.
Enliven Therapeutics, Inc. (ELVN) had negative free cash flow of $65.6M in fiscal year 2025, likely due to heavy capital investments.